Top-Line Summary of Selected Additional Data on Approved Oral Dmts for MS

PRACTICE AID Top-Line Summary of Selected Additional Data on Approved Oral DMTs for MS

This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients.

Agent Trial/Results

• Results for the European cohort of the phase 4 Teri-PRO study showed Teriflunomide high levels of patient-reported treatment satisfaction with teriflunomide; these results are consistent with the overall Teri-PRO study population1

• A subgroup analysis of the PROTEC study showed DMF therapy was associated with lower 12-month ARRs and fatigue score, consistent with findings in the overall study population2 Dimethyl Fumarate • Interim results from the ESTEEM study showed DMF treatment in newly diagnosed, early MS, and interferon/glatiramer acetate switch patients was associated with significantly lower ARRs after 12 months3

• Among patients with RRMS enrolled in the active-comparator study TRANSFORMS and followed for up to 8 years, 35%-52% experienced confirmed improvements in their disability while on fingolimod4

• Data from the PREFERMS study showed that improvements in BVL, cGMVL, and cognition in the injectable DMT group at end of study Fingolimod were associated with a high proportion of switches to fingolimod5

• Results of the TRANSITION study showed fingolimod was effective in controlling clinical disease activity in patients switched from natalizumab; a treatment gap of ≤8 weeks resulted in the lowest risk of relapse; no new safety signals emerged, and AEs decreased with increasing treatment duration6

ARRs: annualized relapse rates; BVL: brain volume loss; cGMVL: cortical gray matter volume loss; DMF: dimethyl fumarate; RRMS: relapsing-remitting multiple sclerosis. 1. Vermersch P et al. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis–Americas Committee for Treatment and Research in Multiple Sclerosis Meeting (MSParis2017). Abstract EP1650. 2. Brochet B et al. MSParis2017. Abstract P1135. 3. Giles K et al. MSParis2017. Abstract P1163. 4. Cree B et al. MSParis2017. Abstract P672. 5. Hunter SF et al. MSParis2017. Abstract P1165. 6. Butzkueven H et al. MSParis2017. Abstract P1213. Access the activity, “Potential Clinical Implications of the Latest Data on Approved and Emerging Disease-Modifying Therapies for Multiple Sclerosis: A Recap From Paris,” at www.peerview.com/SQK40. PRACTICE AID Top-Line Summary of Selected Additional Data on Approved Monoclonal Antibodies for MS

This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients.

Antibody Trial/Results

Data from the TOP registry indicated staying on natalizumab for >2 years yields better clinical outcomes than switching to oral or Natalizumab injectable therapies; for those discontinuing natalizumab, switching to an oral therapy yields better outcomes than switching to an injectable therapy1

6-year follow-up of CARE-MS I and CARE-MS II showed that in the Alemtuzumab absence of continuous treatment, a low proportion of alemtuzumab- treated patients progressed to SPMS2

SPMS: secondary progressive multiple sclerosis. 1. Butzkueven H et al. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis–Americas Committee for Treatment and Research in Multiple Sclerosis Meeting (MSParis2017). Abstract P733. 2. Horakova D et al. MSParis2017. Abstract P1195.

Access the activity, “Potential Clinical Implications of the Latest Data on Approved and Emerging Disease-Modifying Therapies for Multiple Sclerosis: A Recap From Paris,” at www.peerview.com/SQK40. PRACTICE AID Top-Line Summary of Additional Selected Data on Emerging Therapies for MS Management

This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients.

Agent Trial/Results

Pooled data from a phase 2 trial and its ongoing extension indicate that ponesimod 20 mg/day has better clinical and MRI Ponesimod outcomes with a similar safety profile compared with ponesimod 10 mg/day1

Results of the CONCERTO trial showed that although this study did not meet the primary endpoint of time to 3-month CDP, Laquinimod laquinimod 0.6 mg demonstrated a nominally significant effect on reducing BVL and clinical relapses, and was generally well tolerated in patients with RRMS2

SPRINT-MS study showed ibudilast significantly reduced Ibudilast BVL compared with placebo in patients with PPMS and was well tolerated3

BVL: brain volume loss; CDP: confirmed disability progression; PPMS: primary progressive multiple sclerosis; RRMS: relapsing-remitting multiple sclerosis. 1. Havrdova E et al. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis–Americas Committee for Treatment and Research in Multiple Sclerosis Meeting (MSParis2017). Abstract P1151. 2. Comi G et al. MSParis2017. Abstract 233. 3. Fox RJ et al. MSParis2017. Abstract 278.